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INTRODUCTION

In response to domestic pharmaceutical producers' demands, Congress
amended the Federal Food, Drug, and Cosmetic Act (FFDCA) on November 14, 1986.1 The advantages of foreign drug producers over United
States drug producers prompted Congress to enact the Drug Export
Amendments Act of 19862 (DEAA) which was designed to help United
States drug producers compete effectively in the world market.' The
DEAA now puts domestic producers on more of an equal basis with the
rest of the market by allowing them to export unapproved drugs.
The first section of this Note will examine the new amendment and
outline its requirements. Then, it will explore the product liability laws
of New Zealand, Great Britain, and West Germany. This discussion
will present a broad overview of the divergent product liability regimes
employed by various countries. These sections will also serve as a warning to the careless domestic producer. Finally, this Note will critique the
present statute and the resulting opportunities for abuse that arise from
the language of the statute.
II.

DRUG EXPORT AMENDMENTS ACT OF

A.

1986

Purpose of the Amendment

An anomaly existed under the previous FFDCA.4 The Act prohibited
United States producers from exporting new drugs to many countries
where the drugs had already been approved.' This prohibition caused a
large imbalance of trade in the domestic pharmaceutical industry. By
allowing exportation under the DEAA, Congress hopes to cure this
problem.'
Another goal of the DEAA is to encourage producers to develop drugs

1. 21 U.S.C. §§ 301-92 (1982 & Supp. IV 1986).
2. 21 U.S.C. § 382 (Supp. IV 1986).
3. S. REP. No. 225, 99th Cong., 2d Sess. 4 (1985), reprinted in 1986 U.S. CODE
CONG. & ADMIN. NEWS 6298, 6301.

4.

21 U.S.C. § 301 (1982).

5. S. REP. No. 225, supra note 3, at 4, reprinted in 1986 U.S. CODE CONG. &
ADMIN. NEWS at 6301. It is well-publicized that Food and Drug Administration (FDA)
approval is much slower than foreign approval. A 1980 Government Accounting Office
(GAO) survey indicated that over 70% of newly approved drugs were approved in foreign countries before they were approved in the United States. Id. at 5, reprinted in
1986 U.S. CODE CONG. & ADMIN. NEWS at 6302. This difference led to the loss of
domestic jobs and revenue. Id. at 6, reprinted in 1986 U.S CODE CONG. & ADMIN.

NEws at 6303.
6. Id. at 10, reprinted in 1986 U.S. CODE CONG. & ADMIN. NEWs at 6306.
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that can combat diseases which are found in underdeveloped countries
but rarely in the United States.7 Prior to the DEAA, these drugs were
seldom admitted for domestic approval because the absence of a corresponding disease made production of the drugs unprofitable. The DEAA
creates an incentive to aid these afflicted countries. 8 Finally, by imposing
rigorous requirements for exportation, the Act prohibits the dumping of
dangerous drugs.9
B. Analysis of 21 U.S.C. Section 382
1. The "Blanket" Prohibition
The first subsection of the DEAA imposes a blanket prohibition on
the exportation of drugs."0 The statute covers any drug or biological
product that requires approval under the FFDCA or the Virus-SerumToxin Act.1 1 The statute prohibits the exportation of any drug that is
not currently approved, licensed, or exempt from the FFDCA, unless the
new statute's requirements are fulfilled. 12 If the statute's requirements
are not met, the drug is deemed adulterated and misbranded, and exportation of the drug is illegal."3

7. Id. at 12, reprinted in 1986 U.S. CODE CONG. & ADMIN. NEws at 6308.
8. Id. at 12, reprinted in 1986 U.S. CODE CONG. & ADMIN. NEWS at 6308. However, the drug company must actively seek domestic approval of the drug. See infra Part

II, B, 2.
9. See 21 U.S.C. § 382 (Supp. IV 1986). The. FDA has no mechanism to keep a
country from reexporting.
10. 21 U.S.C. § 382(a) (Supp. IV 1986), which states:
A drug (including a biological product) intended for human or animal use (1) which -

(A) requires approval by the Secretary under section 355 of this title or section
360b of this title, or
(B) requires licensing by the Secretary under section 262 of title 42 or by the
Secretary of Agriculture under ... [21 U.S.C. 151 et seq.] . . ., before it may be

introduced or delivered for introduction into interstate commerce to a country, and
(2) which does not have such approval or license, which is not exempt from such
sections or Act, and which is introduced or delivered for introduction into interstate commerce to a country, is adulterated, misbranded, and in violation of such
sections or act unless the export of the drug is authorized under subsection (b) of
this section."

Id. § 382(a).
11. 21 U.S.C. §§ 151-58 (1982 & Supp. IV 1986).
12. 21 U.S.C. § 382(a)(2) (Supp. IV 1986).
13. Id.
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Requirements for Exportation

There are only four types of products that may be exported under the
DEAA: "new drug[s]," "biological products for human use," "biological
product[s] for animal use," and "new animal drug[s].' 4 To obtain approval to export these products, a domestic producer must be "actively"
seeking domestic approval under the appropriate statute."5
Congress also placed restrictions in the statute on the number of countries that may receive the drugs."6 Congress intended to permit exportation only to countries with highly developed drug approval systems. By
limiting the importing countries, Congress sought to avoid the dumping
of hazardous drugs." Not only must the country appear on a statutory
list, but the country must already have approved the product and the

14. Id. § 382(b)(1)(A). This section reads:
A drug (including a biological product) may, upon approval of an application submitted under paragraph (3), be exported if(A) the drug contains the same active ingredient as a(i) new drug(I) which has an exemption under section 355
(i) of this title, and
(II) for which approval is actively being pursued by the person who has the
exemption,
(ii) biological product for human use(I) which has an exemption under section 355
(i) of this title, and
(II) for which licensing of the biological product under section 262 of title 42 is
actively being pursued by the person who has the exemption,
(iii) biological product for animal use(I) for which authority has been granted under the Virus-Serum-Toxin Act [21
U.S.C. § 151 et seq.] for the preparation of an experimental drug product, and
(II) for which the licensing of the biological product under such Act is actively
being pursued by the person who has the authority, or
(iv) new animal drug(I) which has an exemption under section 360b(j) of this title, and
(II) for which approval is actively being pursued by the person who has the
exemption,...
This section cures the previous defect in the FFDCA. Under the Amendment, it is possible to export new unapproved drugs under certain circumstances.
15. Id. Each type of drug has its own corresponding approval process. See supra
note 14.
16. 21 U.S.C. § 382(b)(4)(A) (Supp. IV 1986). These countries are Australia, Austria, Belgium, Canada, Denmark, Federal Republic of Germany, Finland, France, Iceland, Ireland, Italy, Japan, Luxembourg, The Netherlands, New Zealand, Norway,
Portugal, Spain, Sweden, Switzerland, and The United Kingdom.
17. S.Rep. No. 225, supra note 3, at 12, reprinted in 1986 U.S. CODE CONG. &
ADMIN. NEws at 6308.
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product must be available for sale in the country.' 8
There is an exception to the prohibition against exporting to a listed
country that has not approved the drug. If a producer ships to a country
which has not approved the drug and that country reexports the drugs to
an approved country, exportation to the non-approving country is permitted. 9 This exception is justified on the ground that the drug will not
be used in the conduit country and the ultimate receiver is approved. A
country may be added to the statutory list if it has developed a sophisticated drug approval process 2" and if its drug industry maintains high
levels of quality.2
A third requirement for exportation is that the products may not be
disapproved in the United States under its appropriate statutes. 22 A com-

pany may export drugs only when they are either in the domestic approval process or actually have been approved. The fact that a foreign
country has approved a drug bears no weight on the possibility of export
if the drug has been disapproved in the United States by the Secretary of
Health. Also, the drug must be "manufactured, processed, packaged, and
-23
held in conformity with current good manufacturing practice ....
Moreover, various sections of the FFDCA prohibit the adulteration of
drugs.24
The DEAA also requires shipping packages to have a specific label
when exported.2

5

The label must read: "This drug may be sold or offered for sale only in the following countries .... ,,26 Every country

which will receive the drug must be listed on the outside of the package.27 Although there is no legislative history on this requirement, it
seems that a possible purpose for the requirement may be to help enforce
the rule that only specific countries may import these drugs.
Not only must the drug not have been disapproved by the Secretary of
18. 21 U.S.C. § 382(b)(1)(B) (Supp. IV 1986).
19. Id. § 382(b)(2). A problem arises if the drug never leaves the conduit country.
Some commentators claim that the FFDCA has no mechanism to police this problem.
See S. REP. No. 225, supra note 3, at 63-64, reprinted in 1986 U.S. CODE CONG. &
ADMIN. NEWS at 6331-32.
20. 21 U.S.C. § 382(b)(4)(B) (Supp. IV 1986).
21. Id.
22. Id.§ 382(b)(1)(C). This section combined with section 382(b)(1)(A) are the heart
of the DEAA. They conjunctively allow for the shipment of domestically unapproved
drugs.
23. Id. § 382(b)(1)(D).

24. See id.
25.
26.
27.

Id. § 382(b)(1)(E).
Id.
Id.
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Health, but it also must not have been found to be contrary to the public
health of the United States."8 If the Secretary determines that domestic
manufacturing of the drug poses a danger to the United States public
health, it may not be shipped.
Next, the statute cross-references four subsections of the existing
FFDCA that must be fulfilled.2 9 First, the product must be in accordance with the specifications of the foreign purchasers.30 Second, the exportation must not conflict with any of the laws of the importing country."' Third, the package must be labeled "intended for export."3 2
Fourth, the drug must not be sold in the United States33 if it is adulterated or misbranded. 4
The final condition that must be fulfilled prior to exporting the drugs
is that domestic approval must be "actively" sought during the exportation.3 5 "Actively" is defined ambiguously so that it is incumbent upon
the trier of fact to determine if the standard is met. The exporter must
exercise a reasonable "degree of attention" and make a "continuous directed effort" to pursue the approval of the drug. 8
28. Id. § 382(b)(1)(F).
29. Id. § 382(b)(1)(G).
30. 21 U.S.C. § 381(d)(1)(A) (1982).

31.

Id. § 381(d)(1)(B).

32. Id. § 381(d)(1)(C).
33. Id. § 381(d)(1)(D).
34. Id. § 381(d)(1)(D). This subsection appears to be superfluous. The first requirement that the product be in accord with the foreign countries' specifications should be
taken care of by market influences. Id. § 381(d)(1)(A). A domestic producer will not ship
where there is no demand for its products; and, it will only ship what foreigners wish to
purchase.
The second requirement is met by section 382(b)(1)(B), which requires that the drug
be approved in the import country. 21 U.S.C. 382(b)(1)(B) (Supp. IV 1986). One can
assume that if the drug is approved, it will not conflict with the laws of the import
country. Moreover, this second labeling requirement is redundant. Section 382(b)(1)(E)
already requires a label. Id. § 382(b)(1)(E).
The fourth requirement prohibits the sale of the drug in domestic commerce. The
DEAA allows exportation of unapproved drugs. If the drug is unapproved, it can never
be offered for sale in domestic commerce notwithstanding the DEAA. Finally, the drug
cannot be misbranded or adulterated. The blanket prohibition fulfills this requirement.

d. § 382(a).
35. See 21 U.S.C. § 382 (Supp. IV 1986).
36. The statute reads in part:
The Secretary shall determine that an applicant is actively pursuing the approval
or licensing of a drug if the applicant has demonstrated that degree of attention
and continuous directed effort as may reasonably be expected from, and are ordinarily exercised by, a person before approval or licensing of a drug, such as the
preparation for and the conduct of preclinical or clinical investigations, the analy-
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3. Application Requirements
An application for export is required of any entity that desires to ship
drugs abroad. The application must be submitted ninety days before the
proposed shipment date."7 The application is both informational and
representational. It must set forth the proposed drug and the country and
persons who will receive the drug. 8 The exporter must identify the producers of the drug 39 and it must indicate the origin of the exemption or
authority under which the drug is to be exported.40
In addition to this factual information, an applicant must also make
certain representations. First, the statute requires a certification that the
exporter will ship only to enumerated countries and only in amounts
that may reasonably be sold.41 An applicant may ship to a conduit country only if it is shipping there solely for purposes of reexportation. 2
Second, the exporter must certify that the drug is approved in the foreign
country and has not been withdrawn from sale. 3 Third, the exporter
must represent that it has met all of the requirements for exportation.44
Fourth, the domestic producer must certify that it is taking active measures to obtain domestic approval of the drug.45 Finally, a written agreement from each receiving country, stating that no reexportation to an
unapproved country will occur, must be produced by the applicant.4
Once an application is submitted, the Secretary of Health has thirty
days to review it.4" If all the necessary information and certifications
have been submitted, the Secretary will conditionally approve the appli-

sis of the results of such investigations, conferences on such investigations with
government officials, and the preparation of an application of approval or licensing
for the drug.
Id. § 382(b)(1).
37. Id. § 382(b)(3)(A).
38. Id. § 382(b)(3)(B)(i)-(ii).
39. Id. § 382(b)(3)(B)(vi).
40. Id. § 382(b)(3)(B)(v).
41. Id. § 382(b)(3)(B)(iii)(I).
42. Id. This exception is one of the serious flaws in the statute. One of the major
safeguards imposed by Congress was to require that the drug be approved in the foreign
country. The FDA has no mechanism to prevent the drugs from remaining in the conduit country that has not approved the drugs. This lack of enforcement ability undermines the safeguards in the statutory scheme.
43. Id. § 382(b)(3)(B)(iii)(II).
44. Id.§ 382(b)(3)(B)(iii)(III)-(V); see supra notes 14-36 and accompanying text.
45. 21 U.S.C. § 382(b)(3)(B)(iv) (Supp. IV 1986).
46. Id. § 382(b)(3)(B)(vii).
47. Id. § 382(b)(3)(C)(i).
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cation.4 If the certification concerning foreign approval of the drug is in
order, the application will automatically be approved within five days of
the conditional approval.49
4.

Reporting Requirements

The statute imposes four main reporting requirements on domestic
producers. A producer must notify the Secretary within fifteen days if
any of the following events occur: a receiving country has withdrawn
approval of the drug; a receiving country has withdrawn the drug from
sale; or, a producer has withdrawn the drug from the domestic approval
process.5 0 In addition, domestic producers must notify the Secretary
within fifteen days of the receipt of any information that reexportation is
occurring." x Finally, the statute requires exporters to file an annual report with the Secretary of Health. 2
The producer must cease exportation of the drug if the receiving country withdraws the approval of the drug or if the drug is withdrawn from
sale or if a domestic producer withdraws its application for domestic approval, or if the domestic approval application is denied. 53
5.

Tropical Disease Allowance

The DEAA specifically permits the exportation of a drug produced to
combat a tropical disease. 54 Requirements similar to those discussed in
the preceding sections are imposed. Additionally, the Secretary must find
that the drug is safe and effective for treating a tropical disease. 5 This
determination must be based on "credible scientific evidence" and

48. Id.
49. Id. An applicant may amend its application if it later decides to export to an
additional approved country. This amendment should be submitted thirty days prior to
the anticipated shipment date. Id. § 382(b)(3)(D).
50. Id. § 382(c)(1)(A)-(C).
51. Id. § 382(c)(1)(D).
52. Id. § 382(c)(2). The section provides:
The holder of an approved application under subsection (b) of this section authorizing the export of a drug shall report annually to the Secretary after the date of
the approval of the application of the actions taken by the holder in pursuit of the
approval of such drug during the year reported on. Not later than 90 days from
the date of the receipt of a report under this paragraph the Secretary shall determine if the holder is actively pursuing the approval of such drug.

Id.
53.
54.
55.

Id. § 382(d).
Id. § 382(0.
Id. § 382(f)(1)(A).
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"clinical investigations.

'56

To ship a drug produced to combat a tropical disease, the producers
must again obtain the permission of the Secretary. In addition to the
requirements discussed above, the applicant must demonstrate the manner in which the drug will combat the tropical disease."
The reporting requirements for the tropical disease drug application
are less burdensome than those for the regular export application. The
producer has two requirements. It must report the receipt of any information concerning the existence of reexportation, 8 and it must report
any adverse reaction the drug may cause.59
The statute contains enforcement mechanisms specific to the tropical
disease drug allowance. If the drug fails to meet all conditions for exportation or if the producer fails to meet its reporting requirements or if the
manufacture of the drug poses a threat to the public health of the United
States, the Secretary will provide the exporter with notice of the defect."
The holder of an approved application has thirty days to correct such
defects.6 1 Other changes in circumstance will result in an immediate prohibition. If reexportation of the drug to an unapproved country occurs
and this exportation poses an "imminent hazard to the public health,"
exportation is immediately prohibited. 2 An immediate prohibition will
also occur if an exporter ships to a country that does not meet all the
conditions precedent for receiving a drug and the drug is determined to
be an "imminent hazard to the public health."6 "
6.

Enforcement Mechanisms

The enforcement mechanisms of subsection (e) apply to nontropical
disease drug exportation. Again, the Secretary has the power to prohibit
exportation either immediately or after a defect has gone uncorrected for

56.
57.

Id.
Id. § 382(f)(2)(E); see also supra notes 37-49 and accompanying text.

58. 21 U.S.C. § 382(f(3)(A) (Supp. IV 1986).
59. Id. § 382(f)(3)(B).
60. Id. § 382(O(4)(A)(i)-(iii).
61. Id. § 382(f)(4)(A). The statute also directs that the Secretary give the producer a
written notice showing the reasons for prohibition. If the producer requests, it will be
provided with the opportunity for an informal hearing. Id.

62. Id. § 382(f)(4)(B).
63. Id. § 382(f)(4)(C). In the immediate prohibition area, the holder of the application will be given the opportunity for a speedy hearing. The need for a quick hearing is
bolstered by the fact that the Secretary's determination may not be stayed during the
appellate process. Thus, to avoid potential economic harm to a shipper, a quick hearing
is necessary. Id.
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a specific time period. In a number of circumstances, an exporter has
thirty days to correct a defect or exportation must cease.14 One such defect is if a producer attempts to export outside the four categories of
products." Additionally, exportation may be prohibited if the drug is
adulterated or if it is not manufactured in conformity with good manufacturing practice.66
The exported package must continue to bear the statutory label6 7 and
meet other conditions precedent to approval of export."' If an exporter is
using a reexportation scheme, all of the drugs must leave the conduit
country. 9 The domestic manufacture of the drug must not be contrary to
the public health of the United States.7 0 A producer is given a sixty day
grace period if it is found not to be actively pursuing domestic approval
of the drug. If the producer does not rectify the situation during this
period, shipment must cease.71
There are two situations in which an immediate prohibition will result. The first arises when an importer reexports to an unapproved country;7 2 the second, when a drug is exported directly to an unapproved

country. 3

64. Id. § 382(e)(1).
65. Id. § 382(e)(1)(A); see supra notes 14-17 and accompanying text.
66. 21 U.S.C. § 382(e)(1)(A) (Supp. IV 1986); see supra notes 23-24 and accompanying text.
67. 21 U.S.C. § 382(e)(1)(A) (Supp. IV 1986); see supra notes 25-27 and accompanying text.
68. 21 U.S.C. § 382(e)(1)(A) (Supp. IV 1986); see supra note 29 and accompanying
text.
69. 21 U.S.C. § 382(b)(2).
70. Id. § 382(e)(1)(B).
71. Id. § 382(e)(2).
72. Id. § 382(e)(3).
73. Id. § 382(e)(4). This part of statute appears to be anomolous, for subsection (6)
reads:
If the Secretary receives credible evidence that an importer is exporting a drug to
a country which is not listed under subsection (b)(4) of this section, the Secretary
shall notify the holder of the application authorizing the export of such drug of
such evidence and shall require the holder to investigate the export by such importer and to report to the Secretary within 14 days of the receipt of such notice
the findings of the holder. If the Secretary determines that the importer has exported a drug to such a country, the Secretary shall prohibit such holder from
exporting such drug to the importer unless the Secretary determines that the export by the importer was unintentional.
Id. § 382(c)(6) (emphasis added).
The Secretary does not immediately act upon the receipt of credible information but
rather must make a determination that the importer exported a drug to an unapproved
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C. Criticism
One major flaw of the DEAA is the lack of control the FDA has over
the drugs once they are exported. Problems may arise if approved countries reexport drugs obtained under the DEAA to Third World countries. The statute does not provide for enforcement mechanisms to prevent such shipments. 4 In fact, France, Great Britian and Germany
allow exportation of unapproved drugs to Third World countries. 5
Officials from the FDA admit they have no actual power to enforce
the restrictions on reexportation imposed by the DEAA: "I think that [it]
would be very difficult [to enforce the restrictions] ....

Transshipment

would be the responsibility of the country to which the first shipment is
made ..
,,"7 FDA officials also stated: "[O]nce the exportation is made
and the product is in the foreign country you lose your ability to make
the requirement stick and you lose your ability to police."'77 The result is
that countries may receive drugs despite a prohibition by Congress.
Another criticism concerns the Tropical Disease Section of the Act.7
The fact that the Act provides no guidance as to the definition of a
"tropical disease" may allow drug producers to ship unapproved drugs
that have no relation to the cure of tropical diseases. A definite standard
must be formulated in order to guide drug exporters as well as law enforcement officials. Moreover, the Tropical Disease Section may not be
utilized at all because many American producers have no interest in developing such drugs because they are unprofitable.7 9 Many tropical diseases are found only in poor Third World countries that cannot afford to
pay for costly drugs.
A final criticism may be made with regard to the "imminent hazard"
standard in the enforcement provisions.8" First, the provision only oper-

country. Thus there is a delay of time between the receipt of credible evidence and the
"immediate" prohibition. Moreover, the statute allows a wide exception for unintentional

reexportation. This exception undercuts the rigid prohibition of export to unapproved
countries contained elsewhere in the statute. See id. § 382(e)(4).

74. See id. § 382.
75. See S. REP. No. 225, supra note 3, at 63, reprinted in 1986 U.S. CODE CONG.
& ADMIN. NEws at 6331 (minority views of Sen. Howard Metzenbaum).
76. Id. at 63, reprinted in 1986 U.S. CODE CONG. & ADMIN. NEws at 6331 (minority views of Sen. Howard Metzenbaum).
77. Id. at 63, reprinted in 1986 U.S. CODE CONG. & ADMIN. NEws at 6331.

78. See 21 U.S.C. § 382(0 (Supp. IV. 1986).
79. S. REP. No. 225, supra note 3, at 59, reprinted in 1986 U.S.

CODE CONG. &

ADMIN. NEws at 6327.

80. Id. at 65, reprinted in 1986 U.S. CODE CONG. & ADMIN. NEWS at 6333. Export of drugs must cease if they pose an imminent hazard to the public health. 21 U.S.C.
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ates after the damage has occurred. Second, the standard has been found
to have been met domestically only once in twenty years."1 Yet, since
1971, over 7,000 drugs have been recalled. 2
It is with this statutory scheme and these criticisms in mind that this
Note will examine the product liability laws of the three countries. Issues that are important in examining these laws include: whether a foreign consumer will have proper redress if harm results from a drug;
whether that redress will be available in the consumer's country or the
United States; and whether foreign laws adequately compensate these
victims.
III.

FOREIGN PRODUCT LIABILITY LAWS

The product liability laws of many other countries differ greatly from
those of the United States. There have been movements among countries
to make their laws uniform; true uniformity, however, has yet to be
achieved.8 3 This section will analyze the product liability laws of New
Zealand, Great Britain and West Germany. These countries illustrate
several points on a continuum. First, New Zealand has a regime in
which damages are not available for tort victims."' Thus, a drug producer will bear no liability in New Zealand for injuries caused by its
products. The law of Great Britain permits negligence and breach of
warranty actions against drug producers for injuries caused by their
products.8 5 In contrast, West Germany statutorily imposes strict liability
on producers of defective pharmaceutical products.8 "
A.

New Zealand

1. Background
In the late 1960s New Zealand grappled with the defects of its common-law tort cause of action. Many believed that their current tort sys87
tem was not achieving its dual goals of compensation and deterrence.
§ 382(e)(3)(A)(iii) (Supp. IV 1986).
81. S. REP. No. 225, supra note 3, at 59, reprinted in 1986 U.S.
ADMIN.

NEWS

CODE CONG.

&

at 6333.

Id. at 59, reprinted in 1986 U.S. CODE CONG. & ADMIN. NEWS at 6333.
See infra notes 174-90 and accompanying text.
See infra notes 87-146 and accompanying text.
See infra notes 147-68 and accompanying text.
See infra notes 191-230 and accompanying text.
87. See G. PALMER, COMPENSATION FOR INCAPACITY 23-24 (1979); see also
Brown, Deterrence in Tort and No-Fault: The New Zealand Experience, 73 CALIF. L.
82.
83.
84.
85.
86.

REV.

976 (1985).
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The problem of the uncompensated victim was of great concern in New
Zealand."8 Tort victims were not compensated for their injuries unless
they could prove fault. Statistics revealed that a large percentage of injured people received no compensation. 9 Moreover, when victims were
compensated, much of their award did not reach them. Legal fees and
administrative costs consumed a large portion of the tort plaintiff's recovery.9 0 Another problem with the tort system was the delay in receiving
payment. 1 Despite an injured party's urgent need for funds, maintaining a cause of action for negligence often took years.
Finally, a major goal of tort law-deterrence-was not truly being
promoted. 2 The fact that many tortfeasors had third party insurance
greatly undermined the ability of the tort system to deter injurious actions. The ineffectiveness of criminal sanctions against tortfeasors also
hindered the deterrent effect of the tort system.9 3
These flaws led the government of New Zealand to appoint a commission to investigate and recommend a new system of compensating victims
of injury. 4 This commission, chaired by Mr. Justice Woodhouse, issued
the revolutionary Woodhouse Report that held: "[Wihatever the cause of
incapacity and wherever it might occur, society must no longer tolerate
the grudging and artificial discriminations that until now have blemished
the distribution of public moneys supplied by the community at large."95

88. See G. PALMER, supra note 87, at 23.
89. Id. Surveys from several countries including the United States and Great Britain,
revealed that only 13% to 63% of victims were compensated for various injuries. Id.
Obviously, these figures indicate that a large group of people received no aid.
90. Id. at 23-24.
91. Id. at 24. The New Zealand report often relied on statistics from the United
States. Palmer cited a United States Department of Transportation study that found that
average delay in recovery was roughly four years. Id.
92. G. PALMER, supra note 87, at 24, 35. Many argued that the abolition of tort
liability would lead to a rise in careless activity. Professor Brown refuted this argument.
Brown, supra note 87, at 1001. Professor Brown compared motor accident rates and
motor litigation rates before and after New Zealand introduced its accident compensation
scheme. He hypothesized that if the tort law deterrent effect was lost by implementing a
social insurance scheme, both accidents and utilization should increase. He found that
utilization did increase. This increase, however, was so gradual that it was more likely
related to a wealth effect than the abolition of tort liability. Id. at 985. Moreover, the
accident rate declined steadily after the adoption of the Accident Compensation Act. Id.
at 986-90. Thus, deterrence of accidents did not decline under New Zealand's social
insurance scheme.

93. G. PALMER, supra note 87, at 35.
94. See T. ISON, ACCIDENT COMPENSATION 13 (1980).
95. G. PALMER, supra note 87, at 290. Palmer quotes the Report of the National
Comm. of Inquiry, Compensation and Rehabilitation in Australia, para. 225 (1974). A
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The report was eventually enacted as the Accident Compensation Act in
1972.96
2.

Coverage

The purpose of the Accident Compensation Act is to compensate 9 7 "all
persons who suffer personal injury by accident in New Zealand." '9 8 The
Woodhouse Report set forth the philosophy of this all-encompassing coverage. The report stated that "the general basis of protection should be
bodily injury by accident which is undesigned and unexpected so far as
the person injured is concerned. . . -99 Accident is not defined in the Act
but is used in its ordinary sense.10 0 The Act provides twenty-four hour
coverage, and coverage does not depend on cause or fault. 1
Injury by defective drugs appears to come within the definition of
"personal injury by accident":
Personal injury by accident - (a) includes(i) The physical and mental consequences of any such injury or of the
accident:
(ii) medical ... misadventure....
(b) Except as provided in the last preceding paragraphs [personal injury
by accident], does not include -....
(ii) Damage to the body or mind caused exclusively by disease, infection, or the ageing process." ' 2
Thus, personal injuries caused by drugs appear to be covered by the
03
Act.1
Not only does a facial reading of the Accident Compensation Act appear to cover injury from defective drugs, but the statute is also intended
to cover disastrous responses to medical treatment.'0 4 A major commentator on New Zealand law stated that an "extraordinary drug reaction
similar statement appears in the report of the Royal Comm. of Inquiry, Compensation
for Personal Injury in New Zealand, para. 57 (1967) [hereinafter Woodhouse Report].
96. Accident compensation Act 1972, 1 N.Z. Stat. 521, as amended by 3 N.Z. Stat.
1552 (1982).
97. 3 N.Z. Stat. § 26 (1982).
98. Id. § 27(1).
99. G. PALMER, supra note 87, at 245 (quoting Woodhouse Report, supra note 95,
at para. 289).
100. Id. at 246.
101. T. ISON, supra note 94, at 18.
102. 3 N.Z. Stat. § 2 (1982).
103. Palmer, Accident Compensation in New Zealand: The First Two Years, 25 AM.
J. COMp. L. 1, 38-39 (1977); see also G. PALMER,supra note 87, at 255.
104. G. PALMER, supra note 87, at 255.
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far beyond the ordinary hazards of the treatment" would be covered. 10 5
A review decision further defined medical misadventure as when "a person suffers bodily or mental injury or damage in the course of, and as
part of, the administering to that person of medical aid, care and attention. .. ."16

There is one exception to the all-inclusive coverage of the Act. If a
claim for damages lies in another country, the Accident Compensation
Corporation (the Corporation) can require a claimant to seek damages in
that other country10 7 before recovery may be had under the Act.' 0 8 However, the other country may not allow such a claim. For example, in
Bennett v. Enstrom Helicopter Corp., 10 9 the United States Court of Appeals for the Sixth Circuit held, in applying Michigan's choice of laws
statute, that the law of New Zealand governed in a diversity tort action
and that plaintiff's only remedy was under New Zealand law." 0
Finally, there is a statute of limitations in the Accident Compensation
Act. A claim must be filed in writing within twelve months of accident or
death."' This bar may be removed, however, if the Corporation finds
2
cause.1
3.

Benefits

The major benefit provided by the Act is earnings related compensation (ERC)." 3 ERC is paid to the victim beginning one week after an

105. Id.
106. Id. at 258 (quoting Review Decision R 77/1352). Review decisions are delivered by the Accident Compensation Corporation, 3 N.Z. Stat. § 101 (1982). This particular review decision involved the issue of whether a cause of action in products liability
for defective drugs survived the Act. Most scholars agree that such an accident is covered
by the medical misadventure language of the Act. Therefore common law tort damages
are not available.
107. 3 N.Z. Stat. § 86(1) (1982). See generally Barlow, Conflict of Laws, Product
Liability and the Substantive Law of New Zealand in Bennett v. Enstrom Helicopter
Corp., 7 HASTINGS INT'L & COMP. L. REV. 125 (1983).
108. 3 N.Z. Stat. § 86(3)(b) (1982).
109. 679 F.2d 630 (6th Cir. 1982). This holding precludes a tort plaintiff from recovering any substantial damages.
110. Id. But see Barlow, supra note 107, at 129-30. Barlow argues that the substantive law of New Zealand should have been applied. Thus, the Sixth Circuit should have
used New Zealand's common law action for products liability and allowed the plaintiff
to proceed.

111. 3 N.Z. Stat. § 98(1) (1982).
112. Id. § 98(2).
113. See id. § 59.
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accident. 114 If the accident was work-related, the victim's employer must
pay for the first week of lost wages.1 5
To calculate the amount of ERC available, "earnings" and "relevant
earnings" must first be determined. Earnings are defined by specific inclusions and exclusions.11 It is irrelevant whether the claimant is the
employee of another or self-employed; earnings include "wages, salary,
allowances, . . . holiday pay, overtime pay,... bonuses [and] . . . commissions ....

,,7

"Relevant earnings" is a subset of earnings. Relevant earnings are set
at a figure determined by the Corporation to "fairly and reasonably represent [the accident victim's] normal average weekly earnings." ' 8 The
Corporation looks first at weekly earnings. If this figure is not representative, the Corporation may then look at the preceding twenty-eight
days, or the preceding twelve months." 9 When the injury results in a
temporary loss of earning capacity, ERC is payable at the rate of eighty
percent of relevant earnings. 20 The ceiling on this payment is $600.00
" '
per week. 12
A different set of rules applies when the injury results in a permanent
incapacity. First, an earner's permanent diminution in capacity to earn
must be determined. This figure is calculated by comparing pre-accident
and post-accident earning capacity.122 Next, relevant earnings are multiplied by the percentage diminution in capacity and eighty percent of that
amount is paid to the victim. 1 23 This figure is limited to a ceiling of
114. Id. § 57(6).
115. Id. § 59(1). The qualification that an employer pays the first week of lost wages
only if the accident was work-related was the result of a large lobbying effort launched
by the employers. The first draft of the Act required employers to finance the first week
of ERG without regard to the cause of the accident. Employers successfully argued that
this obligation would place them under too heavy a burden. See G. PALMER, supra note
87, at 98.
116. 3 N.Z. Stat. § 52 (1982). The self-employed person receives many exclusions
including those for income from dividends, interest, rents, leases, bailments, and easements. Id. § 52(3).
117. Id. § 52(1).
118. Id. § 53(1).
119. Id. § 53(2). The Act vests wide discretion in the Corporation and its goal is to
fairly compensate all victims.
120. Id. § 59(l)-(2).

121. Id. § 59(10).
122. Id. § 60(2).
123. Id. § 60(1)(e). For example, suppose a man has his left hand cut off while
fixing his lawn mower. This injury reduces his ability to operate his drill press at work
by 20%. His salary pre-injury was $100.00 per week and post-injury is $80.00 per week.
He has thus suffered a loss of earning capacity of $20.00 and will receive an ERG of
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124
$600.00 per week.
The Act does not have any provision to account for a worker's potential increase in earnings during his lifetime. In fact, in only certain situations may the ERC account for potential loss of earnings. If an employee
is under the age of twenty, an apprentice or in training, an adjustment to
the ERC is allowed. 1 25 At each stage until the age of twenty or until the
completion of the apprenticeship or training, the Corporation projects
the sum that the employee would have earned. 26
A different set of criteria is used to determine compensation in the
case of death of the victim. The Act authorizes the payment of a lump
sum to dependents.'1 7 A dependent is defined as one to whom a person
owed a legal duty of support. Dependency may also arise when the decedent reasonably perceived a moral duty to support another person. 28
The Act contains certain presumptions concerning dependency. A woman is presumed to be totally dependent upon her husband. Similarly,
children under sixteen years of age who live at home are considered to29
tally dependent upon their parents.'
A surviving dependent spouse is entitled to a lump sum payment of
$4,000.00. Surviving dependent children are entitled to lump sum payments of $2,000.00... each with a total cap of $6,000.00 to be paid to the
children of any one decedent.'
Dependents are also entitled to receive
the proportion of the decedent's ERG that the decedent would have received had he or she lived. A totally dependent spouse is entitled to sixty
percent of the ERC that would have been awarded had the decedent
been permanently incapacitated. A minor child who is totally dependent
will receive twenty percent of the ERC. 2 If both parents of a dependent
child die, the minor will receive forty percent of the earner's ERG.' 3 A

$16.00 per week.

124. Id. § 60(8).
125. Id. § 62(1)(a).
126. See id. § 62(1).
127. Id. § 82.
128. See id. § 2.
129. Id. § 85.
130. Id. § 82(b)(i). If a spouse or child is only partially dependent, the Corporation
may exercise discretion in arriving at a figure. Id. §§ 82(a)(ii), (b)(ii).
131. Id. § 82(b)(ii). Thus, if there are more than three dependent children, each will
receive less than $2,000.00.
132. Id. § 65(2)(b). Again, the calculation centers on the distinction between partial
and total dependency. If a person was partially dependent, the Corporation decides the
degree to which that dependent should continue to receive the decedent's ERC.
133. Id. § 65(4). The statute appears only to contemplate payment from one person's
ERC.
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remarried spouse is entitled to a lump sum equal to two years of ERC in
addition to the lump sum paid at the time of death."'
Tort lawyers in New Zealand sought and succeeded in obtaining
awards for noneconomic losses under the Act. 3 ' Some typical tort-like
awards are still recoverable, but they are highly regulated. A victim can
recover against a tortfeasor for the impairment or loss of a bodily function. The Act directs that payment be made in accordance with specified
schedules.13 6 Thus, many injuries have precalculated recovery values.
For example, the total loss of a hand will result in a recovery of
$11,900.00. There is a ceiling of $17,000 that may be awarded for any
injury. 137 If the victim had a preexisting impairment, the Commission
must deduct the percentage that the preexisting impairment comprises of
the whole injury.'3 8
Other noneconomic losses may be covered. A victim may recover a
maximum lump sum of $10,000.00 for "the loss suffered by the person
of amenities or capacity for enjoying life, including loss from disfigurement; and... [p]ain and mental suffering, including nervous shock and
neurosis."' 39 Claims for loss of amenities have been hard to sustain. For
example, when presented with a rugby player who was injured and
could no longer perform at his previous level, the Commission denied his
claim for loss of amenities on the grounds that
[t]he words [of the statute cannot] be read as implying that changes in the
way of life on their own should be compensated. For example, men and
women reach the stage where they can no longer enjoy the wear and tear
on the rugby field. . . .I cannot see in the words [of the statute] any
entitlement to compensation....
, The legislation is not designed to reward those who are able to lead
perfectly normal, healthy, full and active lives.' 4"
The final major category of recovery is pecuniary losses. Funeral expenses are the first type of covered pecuniary loss. A claimant may recover funeral expenses that are reasonable by New Zealand's stan134. Id. § 70(a). This rule applies only if the beneficiary is under the age of sixtythree. If the beneficiary is between age sixty-three and sixty-five, a lump sum equal to
the ERC that would have been paid between the date of remarriage and age sixty-five is
awarded. Id. § 70(b).
135. See Palmer, supra note 103, at 25; see also G. PALMER, supra note 87, at 126;
3 N.Z. Stat. § 79 (1982).
136. 3 N.Z. Stat. § 78.
137. Id. § 78(1).
138. Id. It may be difficult to separate preexisting impairment from exacerbation.
139. Id. § 79.
140. Palmer, supra note 103, at 24-25 (quoting Review Decision 75/R0660).
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dards. a4 ' The second type of pecuniary losses recoverable are "actual and
reasonable expenses and proved losses necessarily and directly resulting
from the injury or death."' 4 2 A number of common law recoveries are
specifically excluded. For example, property loss, loss of opportunity to
make a profit, and loss from inability to perform a contract are ex43
cluded.1
4.

Administration and Appellate Review

A claim for compensation must be submitted in writing. 44 If the accident occurs at work, the claimant must file with the employer; otherwise,
the claimant must file with the Corporation. 4 5 The Corporation then
renders its decision on the claim.
Several levels of review are available to a claimant. The first is a review by the Corporation. If the claimant is not satisfied with the Corporation's decision he or she may appeal to the Commission's Appeal Authority. From there, the claimant may go to the Supreme Court,
Administrative Division and finally to the Court of Appeal.' 46 As a practical matter few cases go beyond the Appeal Authority level. 4 7
B.

Great Britain

Great Britain still relies on its common law traditions for much of its
product liability law. Product liability actions may be brought as breach
of warranty, negligence or breach of statutory duty claims. Great Britain
is subject to the European Economic Community Directive 48 concerning
product liability.

141. 3 N.Z. Stat. § 81 (1982).
142. Id. § 80(1).
143. Id.
144. Id. § 96.
145. Id.
146. Id. § 101-12; see also Harris, Accident Compensation in New Zealand: A
Comprehensive Insurance System, 37 MOD. L. REV. 361 (1974).
147. T. IsoN, supra note 94, at 108.
148. Council Directive of 25July, 1985 on the Approximation of the Laws, Regulations and Administrative Provisions of the Member States Concerning Liabilityfor Defective Products, 28 O.J. EUR. COMM. (No. L 210) 29 (1985) [hereinafter Council Directive; see infra notes 176-91.
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1. Breach of Warranty
The Sale of Goods and Hire Purchase Act establishes warranties that
must accompany all commercial transactions. 49 The Act prohibits implied warranties in contracts for the sale of goods except as specifically
provided.150 First, the Act provides a warranty of merchantable quality.151 This warrants that the goods are fit for the purpose for which
they are commonly bought. This warranty factors in expectations. 5 2
The warranty of merchantable quality is required in every transaction
except when defects are shown to the buyers. If a buyer examines the
goods, any defect that should reasonably have been discovered is not
1 53
under warranty.
The second warranty is a warranty of reasonable fitness for a particular purpose.154 There are several requirements before this warranty may
be enforced. First, the buyer must notify the seller of the particular purpose for which the product is purchased.155 Also, the buyer must show
reliance on the skill and judgment of the seller. 56 Additionally, Britain
retains a privity of contract requirement in order for a plaintiff to sus57
tain a breach of warranty suit.1
Contractual disclaimers of liability are statutorily invalid in Great
Britain. The relevant statute reads: "As against a person dealing as con149. Sale of Goods and Hire Purchase Act, 1979, ch. 54.
150. Id. § 14(1). The statute reads: "Except as provided by this section and section
15 below and subject to any other enactment, there is no implied condition or warranty
about the quality or fitness for any particular purpose of goods supplied under a contract
of sale." Id.
151. Id. § 14(2).
152. Id. § 14(6). The definition of merchantable quality has been a problem for the
courts throughout the years. See Cehave N.V. v. Bremer Handelsgesellschaft, m.b.H.
1976 Q.B. 44 (C.A.). Moreover, the statute does not prescribe whose expectations are to
be judged-those of the consumer or those of the manufacturer.
153. Sale of Goods and Hire Purchase Act, 1979, ch. 54, § 14(2).
154. Id. § 14(3).
155. Id.
156. Id.; see Vacwell Engineering Co., Ltd. v. B.D.H. Chemicals, Ltd., [1971] 1
Q.B. 88. In Vacwell, the plaintiff purchased chemicals from the defendant. When the
plaintiff washed tubes containing the chemicals, water became mixed with the chemicals
and an explosion occurred. The court held there was a two step inquiry to imply a
condition of fitness. First, the court asked whether the buyer informed the seller of the
buyer's particular purpose. Second, the court asked whether the buyer relied on the
seller's skill or judgment. The court found in favor of plaintiff on both issues and allowed
recovery. Id. at 103-04.
157. Winterbottom v. Wright, 10 M & W 109, 152 Eng. Rep. 402 (1842); cf. Prosser, The Fall of the Citadel (Strict Liability to the Consumer), 50 MINN L. REv. 791
(1966).
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sumer, liability for breach of the obligations arising from [section 14] of
the [Sale of Goods Act] ...cannot be excluded or restricted by reference
to any contract term. ' 158 Thus, boilerplate disclaimer provisions may no
longer work to the detriment of the ordinary consumer.
An example of the hardship that may result under section 14(3) is
demonstrated by Daniels & Daniels v. . White & Sons, Ltd. 59 In
Daniels, the plaintiff drank some lemonade that had been purchased by
her husband which contained carbolic acid. She sued the store owner and
the manufacturer. The court held that plaintiff could not recover against
the manufacturer because she had not relied on the manufacturer's skill
or judgment. 6 ' Instead, the court imposed liability on the store owner
who had no way of detecting the problem with the lemonade.'
2.

Negligence

Until 1932, British tort law did not impose a duty of care upon manufacturers. Because consumers were owed no duty, negligence law was
unavailable as a cause of action. Thus, consumers were often without
recourse against manufacturers that committed wrongful acts. Because
the consumers did not directly purchase the goods from the manufacturer, privity of contract often precluded a breach of warranty action.
This situation changed with the decision of Donoghue v. Stevenson.' 2
In Donoghue, the plaintiff found the remains of a snail in a bottle of
ginger beer. The plaintiff was not a purchaser, but merely a consumer,
and thus a breach of warranty action was not available. The court, however, imposed a duty of care on the manufacturer. This duty is now
known as the "neighbor" rule. 6 3 In the majority opinion, Lord Atkin
reasoned that a manufacturer "must take reasonable care to avoid acts or
omissions which you can reasonably foresee would be likely to injure
your neighbor."' 6 4 After Donoghue, a victim who wished to pursue a
negligence claim needed to prove three elements: the existence of a duty,
the breach of the duty, and a causal connection between the breach and
65
the injury.'
This new cause of action was helpful to plaintiffs but it was difficult

158. Unfair Contract Terms Act, 1977, ch. 50, § 6(2) (subsection division omitted).
159. [1938] 4 All E.R. 258 (K.B.).
160. Id. at 263.
161. Id. at 264.
162. 1932 App. Cas. 562 (Scot.).
163. Plummer, ProductsLiability in Britain, 9 ANGLO-AM. L. REv. 65, 69 (1980).
164. Donoghue, 1932 App. Cas. at 599.
165. H. TEBBENS, INTERNATIONAL PRODUCT LIABILITY 51 (1979).
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to prove a breach of the duty. For example, when a product came from a
large manufacturing plant, the plaintiff had a very difficult time proving
a lack of care. This problem was solved in Grant v. AustralianKnitting
Mills, Ltd. 6 There, the court laid down the rule that "negligence is
found as a matter of inference from the existence of defects taken in
connection with all unknown circumstances." 1 6 The court effectively
switched the burden of proof to the defendant to show that the harm was
not caused by a lack of care.
The holdings of Donoghue and Grant have not always been applied
consistently to other cases. In Daniels & Daniels v. R. White & Sons,
Ltd., the court denied plaintiff's claim based on negligence, but allowed
a breach of warranty claim.168 The court seemed to establish a defense
for manufacturers, indicating that they could fulfill their duty of care by
using a foolproof process.1" 9 The facts of Daniels, however, are not easily distinguishable from Donoghue.
3.

Breach of Statutory Duty

The Consumer Safety Act of 1978 provided protection to the consumers of numerous products. 1 ' The Secretary of State is empowered to
promulgate regulations which will ensure that adequate levels of safety
are maintained for products."' The Act, however, expressly excludes

166. 1936 App. Cas. 85 (P.C.). In Grant, the plaintiff purchased underwear. After
wearing it, he developed a severe rash. He discovered that the clothing contained excess
sulphites. The court found that since the manufacturing process was foolproof, someone
must be at fault. Id. at 101.
167. Id.
168. [1938] 4 ALL. E.R. 258 (K.B.).
169. Id. at 261-62. In contrast, the relevant German code provision states:
A person who employs another to do any work is bound to compensate for any
damage which the other unlawfully causes to a third party in the performance of
his work. The duty to compensate does not arise if the employer has exercised
necessary care in the selection of the employee, and, where he has to supply apparatus or equipment or to supervise the work, has also exercised ordinary care as
regards such supply or supervision, or if the damage would have arisen notwithstanding the exercise of such care.
2 BGB § 831 (originally enacted, January 1, 1900), translated in THE GERMAN CIVIL
CODE 136 (I. Forrester, S. Goren, H.-M. Ilgen trans. 1975) (including translation of
amendments through 1975) [hereinafter GERMAN CODE]. This section establishes a major defense for German manufacturers similar to the foolproof process defense found in
British law.
170. Consumer Safety Act, 1978, ch. 38.
171. Id. The Act states that "[t]he Secretary of State may make regulations containing such provision ... as ... appropriate for the purpose of securing that goods are safe.
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medicinal products from its coverage.1" 2 These products are regulated by
the Food and Drug Act and the Medicine Act,1" 3 neither of which creates a private cause of action. 74
4.

European Economic Community Directive

Members of the European Economic Community (EEC) have sought
to unify their laws on product liability for many years.' At the end of
July 1985, the Council of European Communities addressed a Directive
to the member states. x7 This Directive seeks to impose strict liability on
producers for damage from defective products.' 77
The EEC believed that there were many flaws in the product liability
laws of the member countries. The Directive adopted three main goals:
elimination of the distortion in competition among member countries; the
promotion of free trade; and the promotion of equal and adequate consumer protection.'"
Article 1 imposes liability on a producer "for damage caused by a
defect in his product. "'" Through this language, the Council attempted
to impose liability without fault, that is strict liability.' 80 The Directive
defines a defective product as a product that does not meet consumers'
safety expectations.' 8 ' Presentation of the product, use, and time of circulation are factored into the determination of whether a product is
defective.
Article 4 provides a private cause of action. A claimant must prove

." Id. § 1(1); see also Plummer, supra note 163, at 74-75.
172. Consumer Safety Act, 1978, ch. 38, § 9(4)(b). The Act excludes drugs from its
provisions.
173. Id.
174. Plummer, supra note 163, at 76; see also Square v. Model Farm Dairies, Ltd.,
[1939] 2 K.B. 365.
175. See generally HARMONIZATION OF LAWS IN THE EUROPEAN COMMUNITIES:
PRODUCTS LIABILITY, CONFLICT OF LAWS AND CORPORATION LAW (P. Herzog ed.

1983) (papers presented at the Fifth Sokol Colloquium) [hereinafter HARMONIZATION].
176. Council Directive, supra note 148, at 29.
177. Id. The preamble of the Directive repeatedly states that the imposition of liability without fault is the only way to solve the products liability crisis.
178. Id. See generally Note, Products Liability: A Comparison of U.S. and EEC
Approaches, 13 SYRACUSE J. INT'L L. & COM. 155 (1986).
179. Council Directive, supra note 148, art. 1. "Product" is defined as "all movables." However, the Directive excludes agricultural products from the definition of
product, unless they are manufactured industrially. Id. art. 2.
180. Id. Preamble.
181. Id. art. 6. See generally Albanese & Del Duca, Developments in European
Product Liability, 5 DICK. J. INT'L L. 193 (1987).
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"damage, the defect and the causal relationship."'8 2 After the plaintiff
establishes a prima facie case, the defendant has several enumerated defenses. A producer will not be liable if: the defect did not exist at the
time of circulation; the product was not circulated by this manufacturer;
or the state of knowledge at the time of circulation would not allow the
discovery of the defect.'
In addition, the Directive seeks to solve the
problem that arises when the producer of a product is unknown 8 4 and
seems to impose liability jointly and severally on all the suppliers.'
The Directive also attempts to ameliorate a common discovery rule
problem that occurs in tort cases by imposing a three-year statute of
limitations.'8 This limitations period is tolled until the victim is aware,
or should have been aware of the defect, damage, and identity of the
producer. 8 " The Directive also contains a ten-year statute of repose.'
Member states are allowed to impose ceilings on recovery, but they
must not be lower than seventy million ECU.' The Directive is to be
implemented by July of 1988.90 Some have argued that the Directive
does not truly embrace strict liability, but rather contains a negligence
inquiry.' 9 ' If such an interpretation is accurate, then Britain is already
in compliance with the Directive.

182.

Council Directive, supra note 148, art. 4.

183. Id. art. 7. The British pushed hard for the development risk defense found in
Article 7(e). M. WILL, Asides on the Nonharmonization of Products Liability Laws in
Europe, in HARMONIZATION, supra note 175, at 32-37. Article 15 of the Directive allows a member state to void this defense. If they choose to follow this route the commission must be notified and the effects tracked. Council Directive, supra note 148, art. 15.
184. See, e.g., Sindell v. Abbott Laboratories, 26 Cal. 3d 588, 607 P.2d 924, 163 Cal.
Rptr. 132 (1980) (DES victims allowed to recover against industry as a whole).
185. See Council Directive, supra note 148, art. 3(3).
186. Id. art. 10.
187. Id.
188. Id. art. 11.
189. Id. art. 16. An ECU is a European Currency Unit that is used for settling debts
in the EEC. D. LASOK, THE LAWS OF THE ECONOMY IN THE EUROPEAN COMMUNITIES 161 (1980).1
190. Council Directive, supra note 148, art. 19.
191. See, e.g., Stapleton, Products Liability Reform-Real or Illusory?, 6 OXFORD
J. LEGAL STUD. 392, 420-21 (1986) (argument that existence of defect still depends on a
cost benefit inquiry, which also is essentially a negligence inquiry).
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C. West Germany
1. Breach of Warranty
Since 1900, West Germany has been governed by a civil code.192
Thus, all laws relating to product liability are codified. Like Great Britain, West Germany adheres to the rule that a victim must be in privity
of contract with the seller to maintain a breach of warranty action. 93
This rule will bar most tort victims from suing a manufacturer for a
defective product. The main warranty provisions of German sales law
are found in section 459 of the Biirgerliches Gesetzbuch (BGB). A seller
has the duty to warrant that there are no latent defects in the product
and that the product contains its promised qualities. 9 4 A purchaser may
only claim damages if the promised quality is lacking, or if the seller
fraudulently concealed the defect.19 5
One impediment to a buyer's recovery is the requirement that the
warranty be express.' 96 A buyer is thus generally precluded from claiming implied warranties.' 97 Moreover, a seller is not liable for breach of
warranty if a buyer knew or should have known of the defect.' 98 This
rule is inapplicable, however, when the seller has fraudulently concealed
a defect.' 99 A final obstacle to recovery under breach of warranty is that
a seller may validly disclaim liability. The statute voids such disclaimers
only if the defect is fraudulently concealed.20 0
Various quasi-contractual causes of action have also been proposed in
West Germany. These include: contracts for the benefit of third parties;
contracts establishing direct legal relationships between manufacturers
and consumers; and, a form of liability based on representations by manufacturers to the public at large. However, these theories have not been
widely followed by German courts and ultimately have been rejected by

192. GERMAN CODE, supra note 169, at xi.
193. H. TEBBENS, supra note 165, at 69.
194. 2 BGB § 459; see also GERMAN CODE, supra note 169, at 72-73.
195. 2 BGB § 463. The section reads: "If a promised quality in the thing sold was
absent at the time of the purchase, the purchaser may demand compensation for nonperformance, instead of cancellation or reduction. The same applies if the seller has fraudulently concealed a defect." Id.; see also GERMAN CODE, supra note 169, at 73.
196. H. TEBBENS, supra note 165, at 67.
197. Id.
198. 2 BGB § 464; see also GERMAN CODE, supra note 169, at 73.
199. 2 BGB § 464; see also GERMAN CODE, supra note 169, at 73.
200. 2 BGB § 476. The section reads: "An agreement, whereby the obligation of the
seller for warranty against defects in the object is released or limited, is void, if the seller
fraudulently conceals the defect." Id.; see also GERMAN CODE, supra note 169, at 74.
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the German Supreme Court.2 1'
2. Negligence
The West German law of torts is codified in the BGB under the heading entitled "delict." Section 823 sets out the main duty: "A person who,
willfully or negligently, unlawfully injuries the life, body, health, freedom, property or other right of another is bound to compensate him for
any damage arising therefrom. 20 2 The basic elements of the cause of
2
action are a violation of an enumerated interest, culpability and cause. 11
The enumereated interests have been broadly construed. For example,
the categories of life, body and health include death or any adverse interference with one of those categories. 20 ' An infringement of a person's
right to freedom of movement constitutes an infringement of "freedom. ' '2 5 Finally, the ownership rights of property are protected.20 6
Culpability is composed of two elements: unlawfulness and fault. The
majority view is that the element of unlawfulness is satisfied whenever
an enumerated right has been infringed. 20 7 According to this view, any
damage to the victim's body would satisfy the requirement of unlawfulness. This rule has been criticized by scholars as being result oriented.20 8
Fault is defined by statute in terms of negligence: "A person who does
not exercise ordinary care acts negligently."20 9 Such a concept is very
similar to that found in common-law countries.
Causation in German law is broken down into two elements. Both a
"but for" causal element as well as proximate cause must be established
by the plaintiff.210 "But for" causation is simply the common sense notion that the conduct caused the result, whereas proximate cause involves
policy and value judgments. A jury must find that the tortfeasor's conduct significantly increased the risk of harm to the victim.2"' This position is a middle ground between conduct that is the simple cause in fact
201.

See H.

TEBBENS,

supra note 165, at 70-72.

202. 2 BGB § 823; see also GERMAN CODE, supra note 169, at 134.
203. B. MARKESINIS, A COMPARATIVE INTRODUCITON TO THE GEMERAN
TORTS 24 (1986).

LAW OF

204. Id. at 25-27.
205. Id. at 27.
206. Id. at 28.
207. Id. at 40.
208. Id. at 41. These scholars feel the conduct itself should be analyzed to find unlawfulness. Id.
209. 2 BGB § 276; see also GERMAN CODE, supra note 169, at 46.
210. B. MARKESINIS, supra note 203, at 64.
211. See id. at 67-68.
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of the harm and conduct in which the harm was simply foreseeable.2 12
Prior to 1969, the products liability plaintiff bore the difficult burden
of proving that a manufacturer was negligent. Moreover, the judicial
construction of section 831, a due care exception to liability, proved to be
a virtually insurmountable hurdle. The courts transformed this section
into what is, in essence, an absolute defense for manufacturers. So long
as the manufacturer carefully selected and supervised its management,
courts would not hold the manufacturer liable for product liability under
section 823.213 Consequently, plaintiffs had a dismal chance of recovery
in such cases.
21 4
However, in Fowlpest, the supreme court removed these obstacles.
In Fowlpest, a farmer had a veterinarian inject his chickens with a drug
to combat the disease of fowlpest. Instead of preventing fowlpest, many
of the chickens contracted the disease, over 4,000 of which died. The
farmer brought suit against the vaccine manufacturer. The court held
the manufacturer liable under section 823.215
First, the court considered the various contractual provisions of the
BGB. The court concluded that a breach of contract action was not
available to the farmer because he was not in privity with the manufacturer. The court also rejected the plaintiff's proposed quasi-contractual
21 6
theories on the ground that the legal relationships were too tenuous.
The court then turned to section 823. Realizing that section 831 posed
an often insurmountable defense for manufacturers in product liability
cases, the court reversed the burden of proof.21 7 Now, a plaintiff must
show merely a casual link between the product and the damage. 21 8 In

212. Id.
213.

2 BGB § 831(1), which states:

A person who employs another to do any work is bound to compensate for any
damage which the other unlawfully causes to a third party in the performance of

his work. The duty to compensate does not arise if the employer has exercised
necessary care or the selection of the employee, and, where he has to supply appa-

ratus or equipment or to supervise the work, has also exercised ordinary care as
regards such supply or supervision, or if the damage would have arisen notwith-

standing the exercise of such care.
See also GERMAN CODE, supra note 169, at 136.
214. Judgment of Nov. 26, 1968, Bundesgerichtshof, W. Ger., 51 Bundesgerichtshof

in Zivilsachen [BGHZ] 91 [hereinafter Fowlpest], translated in B. MARKESINIS, supra
note 203, at 245; see also Mankiewicz, ProductsLiability-A Judicial Breaktrough in
West Germany, 19 INT'L & COMP. L.Q. 99 (comments on Fowlpest, supra).
215. B. MARKESINIS, supra note 203.
216. Id. at 247-48.
217. Id. at 252-54; see also Mankiewicz, supra note 214, at 99-100.
218.

Mankiewicz, supra note 214, at 112-13.
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defense, the defendant manufacturer must prove absence of fault. The
court held that because the defect is within the manufacturer's "sphere of
risk," it was "appropriate and equitable that he carry the risk of not
being able to prove absence of fault on his part."2' 19 In essence, the law
presumes liability on the defendant and it is the defendant's burden to
rebut this presumption.2 2
3.

Strict Liability

In 1976, West Germany passed regulations that dealt with liability for
defective pharmaceuticals. 2 Section 84 of the BGBI imposes liability on
a pharmaceutical manufacturer in a number of situations. A manufacturer is held liable when the prescribed use of the medicine has injurious
effects that go beyond accepted medical standards. 22 The defect must
arise in the development or manufacture of the product. Also, manufacturers are liable if their directions for the use of their products are not in
conformity with accepted standards.2 2
Recovery against the manufacturer is diminished by any contributory
fault of the plaintiff and is completely barred if the drug is not used in
conformity with the manufacturer's directions.2 24 Plaintiffs may file a
claim for up to three years from the time they gain knowledge of their
injuries.2 2 5 Also, manufacturers cannot absolve themselves of liability
2 26
through an exculpatory clause.

In the event of death, a victim's estate may recover the costs of the
victim's treatment, loss of earnings, funeral expenses, and any support
the decedent legally owed to any dependent. 2 If the drug causes only
personal injury, a victim may recover the costs of treatment, any finan219. Id. at 113.
220.

Id.

221. Arzneimittelgesetz, 24 August 1976, BGBI. I §§ 84-94 [hereinafter BGBI.I].
For a translation, see infra Appendix at 839.
222. BGBI.I, supra note 221, at §§ 84(1).
223. Id. § 84(2).
224. Id. § 85. The statute states: "If the negligence on the part of the injured individual contributed to the occurrence of the injury, then § 254 of the Civil Code shall
apply." Id. Section 254 of the German Civil Code states that "[i]f any fault of the injured party has contributed to causing the damage, the obligation to compensate the in-

jured party and the extent of the compensation to be made depends upon the circumstances, especially upon how far the injury has been caused predominantly by the one or
the other party." 2 BGB § 254(1); see also GERMAN CODE, supra note 169, at 42;
Fleming, Drug Injury Compensation Plans, 30 AM. J. COMP. L. 297, 300 (1982).

225. BGBI.I, supra note 221, at § 90.
226. Id. § 92.
227. Id. § 86(l).
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cial damages and an amount representing any reduction in capacity to
earn. s2 The statute imposes ceilings on these awards. If the drug injures
only one person, there is a lump sum cap of 500,000 deutsche marks
("D)M"), or an annuity of DM 30,000 per year. If more than one person is injured, a lump sum cap of DM 200 million is imposed, or a cap
on annuities of DM 12 million per year.22 9
Section 91 allows for concurring of actions under the strict liability
statute and the civil code remedies. 230 Finally, pharmaceutical manufac231
turers must insure themselves against potential loss.

IV.

CONCLUSION

The varied laws of foreign countries pose distinct advantages and
problems for United States pharmaceutical companies exporting unapproved drugs. These laws create incentives and disincentives to export
drugs that have no true social value.
First, West Germany's strict liability statute should promote cautiousness among domestic pharmaceutical producers. When shipping unapproved drugs to West Germany, a producer faces a heavy risk of liability. Such a result is proper because United States producers should not
be given free license to ship unapproved drugs to foreign countries if
those drugs are dangerous. Granted, these drugs must be approved in the
receiving country as a condition precedent to shipping, but there are
faults inherent in approval processes as demonstrated by the disastrous
harm caused by thalidomide, an approved drug.
In contrast, Great Britain's laws may encourage irresponsibility toward British drug consumers. An American producer could easily rebut
the presumption of negligence in a drug product liability case. A foreign
plaintiff will find it difficult to procure evidence for a trial. It would be
very expensive to hire local counsel and investigators to engage in a factfinding mission on another continent. This cost along with no guaranty
of success at trial will discourage many potential plaintiffs from filing a
product liability suit. The alternative of bringing suit in an American
court will likewise be very expensive. This large expense may very well
preclude recovery. As a result, injured parties may effectively be without
remedy when a significant harm has been suffered. The goals of tort law
do not favor this result-neither should a United States statute.
New Zealand appears to be the worst case scenario. New Zealand's
228.

Id. § 87.

229. Id. § 88.
230. Id. § 91.
231. Id. § 94.
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no fault system completely insulates domestic pharmaceutical producers
from liability for injury to drug consumers. This essentially provides
United States producers with an unrestricted testing ground for new
drugs. Given the decision of the United States Court of Appeals for the
Sixth Circuit in Bennett v. Enstrom Helicopter Corp.,2 32 even a wealthy
New Zealander has no recovery under United States law. This decision
should be reconsidered. By enacting the DEAA, Congress did not intend
to create new areas for the testing of drugs. Rather, it intended to equalize competitive markets for drugs worldwide. Therefore, when a country
chooses to abolish tort liability, the exporter's country should not insulate
the tortfeasor. If a manufacturer's drugs cause harm, meaningful compensation for that harm must be recoverable. Thus, the DEAA poses a
significant hazard to New Zealanders who consume drugs imported from
the United States. Not only must they be wary of imported drugs, but
they must be aware that if injury occurs, they may receive no adequate
compensation.
James C. Grant

232.

679 F.2d 630 (6th Cir. 1982).
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APPENDIX**

Section Sixteen
Liability for Injuries from Pharmaceutical Products

§ 84
Absolute Liability
If an individual has been killed or the body or health of an individual
has been significantly injured as the consequence of the use of a pharmaceutical product intended for use in humans, a product which has been
supplied to the consumer within the territorial scope of this law and
which is subject to the obligation of being officially approved or is exempted from official approval by government ordinance, then the pharmaceutical entrepreneur who has put this pharmaceutical product on the
market within the territorial scope of this law is obligated to compensate
the injured individual for the resulting injury. The liability for damages
exists only if
1. the pharmaceutical product, when used as prescribed, has injurious
effects that exceed the degree that is justifiable according to the findings
of medical science and that have their cause in the area of development
or manufacture, or
2. the injury occurred as the result of labeling or information regarding
use that did not correspond to the findings of medical science.

§ 85
Contributory Negligence
If negligence on the part of the injured individual contributed to the
occurrence of the injury, then § 254 of the Civil Code shall apply.

§ 86
Extent of Liability for Damages in the Event of Death
(1) In the event of death, damages must be paid through reimbursement of the expenses of an attempted treatment and also of the pecuniary prejudice that the deceased individual has suffered as a result of the
fact that during the illness his earning capacity was eliminated or reduced or an increase in his needs had occurred. The individual liable for
damages must furthermore reimburse for burial expenses the individual
whose obligation it is to bear these expenses.
(2) If the deceased individual was in a relationship with a third party
at the time of the injury, whereby he was or could become legally responsible for support of this- party, and if the third party has been deprived of the right to support as a consequence of the death, then the
person liable for damages must pay the third party damages to the extent

** Translated by Judith Lee, Ph.D., Language Services, Knoxville, Tennessee.
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to which the deceased, during the probable duration of his life, would
have been obligated to provide support. The liability for damages also
exists if the third party was conceived but not yet born at the time of the
injury.

§ 87
Extent of Liability of Damages in the Event of Bodily Injury
In the event of injury to body or health, damages must be paid
through reimbursement of the expenses of successful treatment and of
the pecuniary prejudice which the injured individual suffers by the fact
that his earning capacity is eliminated or reduced temporarily or permanently or an increase in his needs has occurred as the result of the
injury.

§ 88
Maximum Amounts
The person liable for damages is liable
1. in the event of the death of injury of one individual, for a maximum
capital amount of five hundred thousand German marks [Deutsche
Mark] or a maximum annuity amount of thirty thousand German marks
per year,
2. in the event of death or injury of several individuals from the same
pharmaceutical product, irrespective of the limits defined in No. 1, for a
maximum capital amount of two hundred million German marks or a
maximum annuity amount of twelve million German marks per year.
If the compensations to be paid to several injured individuals in the event
of Paragraph 1, No. 2, exceed the maximum amounts stipulated in that
clause, then the individual compensations are reduced in proportion to
the ratio of their total amount to the maximum amount.

§ 89
Damages in the Form of Annuities
(1) Damages due to loss of or decrease in earning capacity and due to
increase in the needs of the injured individual and damages to be paid to
a third party in accordance with § 86, Subsection 2 shall be paid for the
future by payment of an annuity.
(2) The provisions of § 843, Sec. 2-4, of the Civil Code and of § 708,
No. 6 of the Code of Civil Procedure shall -apply accordingly.
(3) If, when the liable party is adjudged to pay an annuity, no requirement to furnish security has been imposed, the beneficiary shall
nevertheless be able to demand security if the financial condition of the
liable party has worsened considerably; under the same conditions he can
demand an increase specified in the judgment.

§ 90
Limitation of Actions
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(1) The claim defined in § 84 is subject to a limitation of three years
from the date on which the individual entitled to damages obtains knowledge of the damage, of the conditions from which his right to a claim
results, or of the person of the individual liable damages, [or,] irrespective of this knowledge, of thirty years from the injurious event.
(2) If negotiations regarding the damages to be paid are in progress
between the individual liable for damages and the individual entitled to
damages, then the limitation period is extended until one or the other
party refuses continuation of negotiations.
(3) Otherwise the provisions of the Civil Code regarding limitation of
actions shall apply.

§ 91
More Extensive Liability
Legal regulations according to which an individual liable for damages
under § 84 shall be liable to a greater extent than specified by the provisions of this section, or according to which another individual is responsible for the injury, shall not be affected by this act.

§ 92
Absoluteness
Liability for damages in accordance with this section may not be excluded or limited in advance. Any contrary agreements shall be null and
void.

§ 93
Several Individuals Liable for Damages
If several individuals are liable for damages, then they are jointly and
severally liable. In the same proportion as that of the persons liable for
damages to one another, the liability for damages and the extent of the
damages to be paid depend on the conditions, particularly on the extent
to which the injury has been caused primarily by the one or the other
party.
§ 94
Provision for Sufficient Cover
(1) The pharmaceutical entrepreneur must provide for the possibility
that he must fulfill his legal obligations to pay damages arising from the
use of a pharmaceutical product intended for use in humans that he has
put on the market, a product subject to the obligation of being officially
approved or exempted from official approval by government ordinance
(provision for sufficient cover). The provision for sufficient cover must be
in the amount of the sums specified in § 88 Sec. 1. It can be provided
only
1. by liability insurance with an insurance company authorized to do
business within the territorial scope of this law or
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2. by an indemnity or guarantee obligation from a domestic banking
institution.
(2) If sufficient cover is provided by liability insurance, then §§ 158c158k of the Law on Insurance Policies of May 30, 1908 (Reich Law
Gazette, p. 263), last amended by the Law of June 30, 1967 (Federal
Law Gazette I. p. 609) shall apply correspondingly.
(3) The provision for cover can only be provided by an indemnity or
guarantee obligation from a banking institution if it is guaranteed that,
for the period in which recourse to the banking institution is expected,
the banking institution will be capable of meeting its obligations within
the scope of the provision for cover. §§ 158c and 158k of the law of
Insurance Contracts shall apply correspondingly to the indemnity or
guarantee obligation.
(4) The competent body as defined by § 158c, Subsection 2, of the
Law on Insurance Policies is the competent authority for carrying out
supervision in accordance with § 64.
(5) Neither the Federal Republic of Germany nor its states (Lander)
are obligated to provide cover as defined in Subsection 1.

